699800P
Avanti
MPLA (PHAD™)
Avanti Research™ - A Croda Brand
Synonym(s):
PHAD™ phosphorylated hexaacyl disaccharide; Glycopyranoside Lipid A; GLA
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
Empirical Formula (Hill Notation):
C96H184N3O22P
CAS Number:
Molecular Weight:
1763.47
UNSPSC Code:
12352211
NACRES:
NA.25
Recommended Products
description
Monophosphoryl Lipid A (Synthetic) (PHAD™)
Assay
>99% (HPLC)
form
powder
packaging
pkg of 1 × 1 mg (699800P-1mg)
pkg of 1 × 5 mg (699800P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
application(s)
vaccine development
shipped in
dry ice
storage temp.
−20°C
General description
Monophosphoryl lipid A (MPLA) is either extracted from bacterial lipid A or by chemical synthesis.
Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.
Application
MPLA PHAD™ has been used:
- as a component of cobalt porphyrin-phospholipid (Co-PoP) liposomes for the immunization of mice with membrane proximal external region (MPER) of the gp41 envelope protein
- as an adjuvant along with dimethyldioctadecylammonium bromide(DDA) for C. muridarum recombinant membrane protein based multi-subunit vaccine
- as toll-like receptor-4 (TLR4) agonist adjuvant for respiratory syncytial virus (RSV) fusion (F) protein FI-RSV vaccine
Biochem/physiol Actions
Monophosphoryl lipid A (MPLA) is a natural agonist for the toll-like receptor-4 (TLR4). It is useful as an adjuvant in immunization. MPLA is a safe prophylactic agent and has immunotherapeutic applications. MPLA used in vaccination improves B cell and T cell-mediated immunity.
Packaging
2 mL Amber Glass Crimp Cap Vial (699800P-1mg)
2 mL Amber Glass Crimp Cap Vial (699800P-5mg)
Other Notes
For R&D use only. Not for drug, household, or other uses.
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
PHAD is a trademark of Avanti Polar Lipids, LLC
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Susana Lousada-Dietrich et al.
Vaccine, 29(17), 3284-3292 (2011-02-26)
GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. Here we report a preclinical study screening a series of adjuvant
Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens
Shao S, et al.
Nature Chemistry, 7(5), 438-438 (2015)
Caroline Boudousquié et al.
Vaccines, 8(1) (2020-01-18)
With the emergence of immune checkpoint inhibitors and adoptive T-cell therapies, there is a considerable interest in using personalized autologous dendritic cell (DC) vaccines in combination with T cell-targeting immunotherapies to potentially maximize the therapeutic impact of DC vaccines. Here
Katharina Richard et al.
Vaccine, 38(27), 4298-4308 (2020-05-12)
Toll-like receptors (TLRs), a family of "pattern recognition receptors," bind microbial and host-derived molecules, leading to intracellular signaling and proinflammatory gene expression. TLR4 is unique in that ligand-mediated activation requires the co-receptor myeloid differentiation 2 (MD2) to initiate two signaling
Rhea N Coler et al.
PloS one, 6(1), e16333-e16333 (2011-02-08)
Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service